文献速递技术与安全PETCT

基线与中期[68Ga]Ga-DOTA-TOC PET/CT对接受肽受体放射性核素治疗的神经内分泌肿瘤患者的预后价值

Prognostic value of interim [68Ga]Ga-DOTA-TOC PET/CT in patients with neuroendocrine tumour who underwent peptide receptor radionuclide therapy.
PubMed 文献 · Eur Radiol · 2024-10-22

该回顾性研究纳入24例接受[177Lu]Lu-DOTA-TATE肽受体放射性核素治疗(PRRT)的神经内分泌肿瘤(NET)患者,分析基线与中期(2周期PRRT后)[68Ga]Ga-DOTA-TOC PET/CT参数变化与无进展生存期(PFS)的关系。结果显示,高∆WTV(≥-10%)和高∆TRE(≥-21%)与更短PFS显著相关,多因素分析中仍为显著预测因子。

要点

  • 中期[68Ga]Ga-DOTA-TOC PET/CT的∆WTV和∆TRE变化可用于预测PRRT治疗的PFS。
  • ∆WTV≥-10%和∆TRE≥-21%提示更短PFS,多因素分析中风险比分别为3.345和3.894。
  • 基线与中期[68Ga]Ga-DOTA-TOC PET/CT通过WTV和TRE proportional变化有效预测PFS。

核心结论

  • 基线与中期[68Ga]Ga-DOTA-TOC PET/CT扫描,通过WTV和TRE的 proportional变化,能有效预测接受PRRT的神经内分泌肿瘤患者的PFS。

研究设计与样本

  • 回顾性研究,纳入24例在本机构接受[177Lu]Lu-DOTA-TATE PRRT且完成基线与中期(2周期PRRT后)[68Ga]Ga-DOTA-TOC PET/CT的局部晚期或转移性NET患者;获取SUVmax、TLR、WTV和TRE及其 proportional变化(∆),采用Kaplan-Meier分析、log-rank检验和Cox比例风险回归模型评估与PFS的关联。

诊断标准与关键数值

  • 单因素分析中,高∆WTV(≥-10%,HR=3.053 [1.003-9.289],p=0.049)和高∆TRE(≥-21%,HR=3.567 [1.144-11.122],p=0.028)与更短PFS显著相关;多因素分析校正WHO分级后,高∆WTV(HR=3.345 [1.055-10.601],p=0.043)和高∆TRE(HR=3.894 [1.194-12.695],p=0.024)为更短PFS的显著预测因子。

临床应用与阅片要点

  • 中期[68Ga]Ga-DOTA-TOC PET/CT可作为有价值的影像方法预测PRRT的预后。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVES: This study evaluated the prognostic value of basal and interim [68Ga]Ga-DOTA-TOC PET/CT in patients with locally advanced or metastatic neuroendocrine tumour (NET) who received peptide receptor radionuclide therapy (PRRT).

METHODS: Patients with NET who received PRRT with [177Lu]Lu-DOTA-TATE at our institution were retrospectively reviewed. Among them, patients who underwent both basal and interim (after two cycles of PRRT) [68Ga]Ga-DOTA-TOC PET/CT were included. Alongside clinicopathologic parameters, PET parameters of maximum standardised uptake value (SUVmax), tumour-to-liver ratio (TLR), whole tumour volume (WTV) and total receptor expression (TRE: WTV multiplied by mean standardised uptake value) were obtained from basal and interim [68Ga]Ga-DOTA-TOC PET/CT, and their proportional changes (∆) were assessed for associations with progression-free survival (PFS) using Kaplan-Meier analysis, log-rank tests, and a Cox proportional-hazards regression model.

RESULTS: Twenty-four patients were finally included (10 men and 14 women, median age of 56.5 years, age range 32-74 years). Among them, 16 patients (66.7%) experienced disease progression. In univariate analysis, high ∆WTV (≥ -10%, hazard ratio [HR] = 3.053 [1.003-9.289], p = 0.049) and high ∆TRE (≥ -21%, HR = 3.567 [1.144-11.122], p = 0.028) were significantly associated with shorter PFS. In multivariate analyses adjusted for WHO grade, high ∆WTV (HR = 3.345 [1.055-10.601], p = 0.043) and high ∆TRE (HR = 3.894 [1.194-12.695], p = 0.024) were significant predictors of shorter PFS.

CONCLUSION: The study demonstrates that basal and interim [68Ga]Ga-DOTA-TOC PET/CT scans, through proportional changes in WTV and TRE, effectively predict PFS in neuroendocrine tumour patients receiving PRRT.

KEY POINTS: Question Peptide receptor radionuclide therapy is utilised for patients with somatostatin receptor-positive well-differentiated neuroendocrine tumours; however, prognostic predictors are not well established. Findings Progression-free survival was significantly associated with the proportional change in whole tumour volume and total receptor expression between basal and interim [68Ga]Ga-DOTA-TOC PET/CT. Clinical relevance Interim [68Ga]Ga-DOTA-TOC PET/CT can serve as a valuable imaging method to predict prognosis of peptide receptor radionuclide therapy.

来源:Eur Radiol,查看原文。版权归原作者所有。

引用

  1. Shin E, Kim YI, Yoo C, et al. Prognostic value of interim [68Ga]Ga-DOTA-TOC PET/CT in patients with neuroendocrine tumour who underwent peptide receptor radionuclide therapy. Eur Radiol. 2024. PMID: 39436411. doi:10.1007/s00330-024-11116-5

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。